A predicted protein, KIAA0247, is a cell cycle modulator in colorectal cancer cells under 5-FU treatment

Journal of Translational Medicine

Volumn 9, Issue , 2011, Pages

  Huang, Chi Jung ^a,b,c   Yang, Shung Haur ^d   Huang, Shih Ming ^b   Lin, Chih Ming ^a,c   Chien, Chih Cheng ^a,c   Chen, Yan Chu ^b   Lee, Chia Long ^c   Wu, Hao Han ^d   Chang, Chun Chao ^e  

^a FU JEN CATHOLIC UNIVERSITY   (Taiwan)

^b NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^c CATHAY GENERAL HOSPITAL   (Taiwan)

^d NATIONAL YANG MING UNIVERSITY   (Taiwan)

^e TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN A2; CYCLIN B1; CYCLIN B2; FLUOROURACIL; MESSENGER RNA; PROTEIN KIAA0247; PROTEIN P53; TUMOR PROTEIN; UNCLASSIFIED DRUG; COMPLEMENT; CYCLINE; KIAA0247 PROTEIN, HUMAN;

AGED; ARTICLE; CANCER SIZE; CARCINOGENESIS; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE REGULATION; CELL NUCLEUS; CELL STRAIN HCT116; COLON MUCOSA; COLORECTAL CANCER; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYCLIN A2 GENE; CYCLIN B1 GENE; CYCLIN B2 GENE; CYTOPLASM; DRUG MECHANISM; DRUG RESPONSE; FECES ANALYSIS; FEMALE; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE TEST; LINKAGE ANALYSIS; LIVER PARENCHYMA; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; OVERALL SURVIVAL; PANCREAS; PERIPHERAL LYMPHOCYTE; PROTEIN AGGREGATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; REAL TIME POLYMERASE CHAIN REACTION; SMALL INTESTINE; SPLEEN; SURVIVAL TIME; CELL CYCLE; CELL DIVISION; COLON; COLORECTAL TUMOR; DRUG EFFECT; FECES; GENETICS; INTRACELLULAR SPACE; METABOLISM; PATHOLOGY; PROTEIN TRANSPORT; SURVIVAL;

AGED; CELL CYCLE; CELL DIVISION; COLON; COLORECTAL NEOPLASMS; COMPLEMENT SYSTEM PROTEINS; CYCLINS; FECES; FEMALE; FLUOROURACIL; G2 PHASE; GENE EXPRESSION REGULATION, NEOPLASTIC; HCT116 CELLS; HUMANS; INTRACELLULAR SPACE; MALE; PROTEIN TRANSPORT; RNA, MESSENGER; SURVIVAL ANALYSIS;

EID: 79957484840     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-9-82     Document Type: Article

References (38)

1. Lieberman D. Progress and challenges in colorectal cancer screening and surveillance. Gastroenterology 2010, 138:2115-2126. 10.1053/j.gastro.2010.02.006, 20167216.
2. Kim MS, Lee J, Sidransky D. DNA methylation markers in colorectal cancer. Cancer Metastasis Rev 2010, 29:181-206. 10.1007/s10555-010-9207-6, 20135198.
3. Allegra C, Sargent D. Molecular diagnostics: assays, tissues, progress, and pitfalls. J Clin Oncol 2003, 21:395-396. 10.1200/JCO.2003.11.073, 12560423.
4. Lagerholm S, Lagerholm S, Dutta S, Nair P. Non-invasive detection of c-myc p64, c-myc p67 and c-erbb-2 in colorectal cancer. Scand J Gastroenterol 2005, 40:1343-1350. 10.1080/00365520510023549, 16334444.
5. Vogelstein B, Fearon ER, Hamilton SR. Genetic alterations during colorectal-tumor development. N Engl J Med 1988, 319:525-532. 10.1056/NEJM198809013190901, 2841597.
6. Macarulla T, Ramos FJ, Capdevila J, Saura C, Tabernero J. Novel targets for anticancer treatment development in colorectal cancer. Clin Colorectal Cancer 2006, 6:265-272. 10.3816/CCC.2006.n.045, 17241511.
7. Voutsadakis IA. Pathogenesis of colorectal carcinoma and therapeutic implications: the roles of the ubiquitin-proteasome system and Cox-2. J Cell Mol Med 2007, 11:252-285. 10.1111/j.1582-4934.2007.00032.x, 17488476.
8. DiPaola RS. To arrest or not to G(2)-M Cell-cycle arrest: commentary re: A. K. Tyagi et al., Silibinin strongly synergizes human prostate carcinoma DU145 cells to doxorubicin-induced growth inhibition, G(2)-M arrest, and apoptosis. Clin. cancer res., 8: 3512-3519, 2002. Clin Cancer Res 2002, 8:3311-3314.
9. Owa T, Yoshino H, Yoshimatsu K, Nagasu T. Cell cycle regulation in the G1 phase: a promising target for the development of new chemotherapeutic anticancer agents. Curr Med Chem 2001, 8:1487-1503.
10. Carlson B, Lahusen T, Singh S, Loaiza-Perez A, Worland PJ, Pestell R, Albanese C, Sausville EA, Senderowicz AM. Down-regulation of cyclin D1 by transcriptional repression in MCF-7 human breast carcinoma cells induced by flavopiridol. Cancer Res 1999, 59:4634-4641.
11. Hirose Y, Berger MS, Pieper RO. Abrogation of the Chk1-mediated G(2) checkpoint pathway potentiates temozolomide-induced toxicity in a p53-independent manner in human glioblastoma cells. Cancer Res 2001, 61:5843-5849.
12. Robles AI, Bemmels NA, Foraker AB, Harris CC. APAF-1 is a transcriptional target of p53 in DNA damage-induced apoptosis. Cancer Res 2001, 61:6660-6664.
13. Staib F, Robles AI, Varticovski L, Wang XW, Zeeberg BR, Sirotin M, Zhurkin VB, Hofseth LJ, Hussain SP, Weinstein JN, et al. The p53 tumor suppressor network is a key responder to microenvironmental components of chronic inflammatory stress. Cancer Res 2005, 65:10255-10264. 10.1158/0008-5472.CAN-05-1714, 1421332, 16288013.
14. Kanaoka S, Yoshida K, Miura N, Sugimura H, Kajimura M. Potential usefulness of detecting cyclooxygenase 2 messenger RNA in feces for colorectal cancer screening. Gastroenterology 2004, 127:422-427. 10.1053/j.gastro.2004.05.022, 15300574.
15. Kawada M, Mizuno M, Nasu J, Uesu T, Okazaki H, Okada H, Shimomura H, Yamamoto K, Tsuji T, Fujita T, et al. Release of decay-accelerating factor into stools of patients with colorectal cancer by means of cleavage at the site of glycosylphosphatidylinositol anchor. J Lab Clin Med 2003, 142:306-312. 10.1016/S0022-2143(03)00137-9, 14647034.
16. Yang SH, Chien CC, Chen CW, Li SY, Huang CJ. Potential of faecal RNA in diagnosing colorectal cancer. Cancer Lett 2005, 226:55-63. 10.1016/j.canlet.2004.11.005, 16004932.
17. Chang CC, Yang SH, Chien CC, Chen SH, Pan S, Lee CL, Lin CM, Sun HL, Huang CC, Wu YY, et al. Clinical meaning of age-related expression of fecal cytokeratin 19 in colorectal malignancy. BMC Cancer 2009, 9:376. 10.1186/1471-2407-9-376, 2776602, 19849844.
18. Huang CJ, Chien CC, Yang SH, Chang CC, Sun HL, Cheng YC, Liu CC, Lin SC, Lin CM. Faecal ribosomal protein L19 is a genetic prognostic factor for survival in colorectal cancer. J Cell Mol Med 2008, 12:1936-1943.
19. Yang RN, Yang SH, Chang CC, Chien CC, Pan S, Huang CJ. Upregulation of fecal cytokeratin 19 is associated with prognosis in older colorectal cancer patients. Genet Test Mol Biomarkers 2010, 14:703-708. 10.1089/gtmb.2010.0047, 20854102.
20. Li J, Tan J, Zhuang L, Banerjee B, Yang X, Chau JF, Lee PL, Hande MP, Li B, Yu Q. Ribosomal protein S27-like, a p53-inducible modulator of cell fate in response to genotoxic stress. Cancer Res 2007, 67:11317-11326. 10.1158/0008-5472.CAN-07-1088, 18056458.
21. Miyake H, Hanada N, Nakamura H, Kagawa S, Fujiwara T, Hara I, Eto H, Gohji K, Arakawa S, Kamidono S, et al. Overexpression of Bcl-2 in bladder cancer cells inhibits apoptosis induced by cisplatin and adenoviral-mediated p53 gene transfer. Oncogene 1998, 16:933-943. 10.1038/sj.onc.1201602, 9484785.
22. Cubas R, Zhang S, Li M, Chen C, Yao Q. Trop2 expression contributes to tumor pathogenesis by activating the ERK MAPK pathway. Mol Cancer 2010, 9:253. 10.1186/1476-4598-9-253, 2946292, 20858281.
23. Chang CC, Chien CC, Yang SH, Chen SH, Huang CJ. Identification and Clinical Correlation of Decreased Expression of Cytoplasmic Dynein Heavy Chain 1 in Patients with Colorectal Cancer. Clin Mol Medicine 2008, 1:6-10.
24. Fingerle-Rowson G, Petrenko O. MIF coordinates the cell cycle with DNA damage checkpoints. Lessons from knockout mouse models. Cell Div 2007, 2:22. 10.1186/1747-1028-2-22, 1941730, 17640378.
25. Yeh YH, Huang YF, Lin TY, Shieh SY. The cell cycle checkpoint kinase CHK2 mediates DNA damage-induced stabilization of TTK/hMps1. Oncogene 2009, 28:1366-1378. 10.1038/onc.2008.477, 19151762.
26. Taylor WR, Stark GR. Regulation of the G2/M transition by p53. Oncogene 2001, 20:1803-1815. 10.1038/sj.onc.1204252, 11313928.
27. Agarwal ML, Agarwal A, Taylor WR, Stark GR. p53 controls both the G2/M and the G1 cell cycle checkpoints and mediates reversible growth arrest in human fibroblasts. Proc Natl Acad Sci USA 1995, 92:8493-8497. 10.1073/pnas.92.18.8493, 41183, 7667317.
28. Hermeking H, Lengauer C, Polyak K, He TC, Zhang L, Thiagalingam S, Kinzler KW, Vogelstein B. 14-3-3 sigma is a p53-regulated inhibitor of G2/M progression. Mol Cell 1997, 1:3-11. 10.1016/S1097-2765(00)80002-7, 9659898.
29. Concin N, Stimpfl M, Zeillinger C, Wolff U, Hefler L, Sedlak J, Leodolter S, Zeillinger R. Role of p53 in G2/M cell cycle arrest and apoptosis in response to gamma-irradiation in ovarian carcinoma cell lines. Int J Oncol 2003, 22:51-57.
30. Bache M, Dunst J, Wurl P, Frode D, Meye A, Schmidt H, Rath FW, Taubert H. G2/M checkpoint is p53-dependent and independent after irradiation in five human sarcoma cell lines. Anticancer Res 1999, 19:1827-1832.
31. Chung JH, Bunz F. Cdk2 is required for p53-independent G2/M checkpoint control. PLoS Genet 2010, 6:e1000863. 10.1371/journal.pgen.1000863, 2829054, 20195506.
32. Gangadhar T, Schilsky RL. Molecular markers to individualize adjuvant therapy for colon cancer. Nat Rev Clin Oncol 2010, 7:318-325. 10.1038/nrclinonc.2010.62, 20440283.
33. Wang BD, Kline CL, Pastor DM, Olson TL, Frank B, Luu T, Sharma AK, Robertson G, Weirauch MT, Patierno SR, et al. Prostate apoptosis response protein 4 sensitizes human colon cancer cells to chemotherapeutic 5-FU through mediation of an NF kappaB and microRNA network. Mol Cancer 2010, 9:98. 10.1186/1476-4598-9-98, 2883962, 20433755.
34. Sasaki K, Tsuno NH, Sunami E, Tsurita G, Kawai K, Okaji Y, Nishikawa T, Shuno Y, Hongo K, Hiyoshi M, et al. Chloroquine potentiates the anti-cancer effect of 5-fluorouracil on colon cancer cells. BMC Cancer 2010, 10:370. 10.1186/1471-2407-10-370, 2914703, 20630104.
35. Cunningham D, Atkin W, Lenz HJ, Lynch HT, Minsky B, Nordlinger B, Starling N. Colorectal cancer. Lancet 2010, 375:1030-1047. 10.1016/S0140-6736(10)60353-4, 20304247.
36. Oka K, Tanaka T, Enoki T, Yoshimura K, Ohshima M, Kubo M, Murakami T, Gondou T, Minami Y, Takemoto Y, et al. DNA damage signaling is activated during cancer progression in human colorectal carcinoma. Cancer Biol Ther 2010, 9:246-252. 10.1158/1535-7163.MCT-09-0495, 2977911, 20023412.
37. Wei EK, Wolin KY, Colditz GA. Time course of risk factors in cancer etiology and progression. J Clin Oncol 2010, 28:4052-4057. 10.1200/JCO.2009.26.9324, 20644083.
38. Chien CC, Chang CC, Yang SH, Chen SH, Huang CJ. A homologue of the Drosophila headcase protein, HECA, is a novel tumor marker for early-stage colorectal cancer. Oncol Rep 2006, 15:919-926.